MDS 2026 — PD Genetic and Molecular Mechanisms

📖 Wiki Page

mechanism1422 wordssynced 2026-04-02

MDS 2026 — Parkinson's Disease Genetic and Molecular Mechanisms

Congress: Movement Disorder Society (MDS) International Congress 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Dates: October 4-8, 2026

This page synthesizes the latest research on Parkinson's disease genetics and molecular mechanisms presented at MDS 2026, with emphasis on key genetic risk factors, molecular pathways, and therapeutic implications.

Overview

MDS 2026 showcased significant advances in understanding the genetic architecture of Parkinson's disease and the molecular mechanisms underlying neurodegeneration. Key themes included:

LRRK2 biology: Kinase inhibitors advancing to late-stage trials
GBA-associated PD: Recognition as a distinct clinical subtype
Alpha-synuclein biology: Seed amplification assays reaching clinical validation
Emerging genetic risk factors: New loci identified through multi-ethnic GWAS
Polygenic risk scores: Moving toward clinical implementation

1. LRRK2 Pathway and Therapeutic Targeting

Genetic Basis

[LRRK2](/genes/lrrk2) (Leucine-Rich Repeat Kinase 2) is the most common monogenic cause of Parkinson's disease[@cookson2023]. Pathogenic variants include:

| Variant | Domain | Effect | Population Prevalence |
|---------|--------|--------|----------------------|
| G2019S | Kinase | ↑ Kinase activity 2-3x | ~5% familial, ~1% sporadic PD |
| R1441C/G/H | ROC | ↓ GTPase activity | Basque, worldwide |
| I2020T | Kinase | ↑ Kinase activity | Japanese families |

Molecular Mechanisms

...

MDS 2026 — Parkinson's Disease Genetic and Molecular Mechanisms

Congress: Movement Disorder Society (MDS) International Congress 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Dates: October 4-8, 2026

Overview

MDS 2026 showcased significant advances in understanding the genetic architecture of Parkinson's disease and the molecular mechanisms underlying neurodegeneration. Key themes included:

LRRK2 biology: Kinase inhibitors advancing to late-stage trials
GBA-associated PD: Recognition as a distinct clinical subtype
Alpha-synuclein biology: Seed amplification assays reaching clinical validation
Emerging genetic risk factors: New loci identified through multi-ethnic GWAS
Polygenic risk scores: Moving toward clinical implementation

1. LRRK2 Pathway and Therapeutic Targeting

Genetic Basis

[LRRK2](/genes/lrrk2) (Leucine-Rich Repeat Kinase 2) is the most common monogenic cause of Parkinson's disease[@cookson2023]. Pathogenic variants include:

Molecular Mechanisms

LRRK2 participates in multiple cellular pathways relevant to PD pathogenesis:

Rab GTPase phosphorylation: Regulates vesicle trafficking

Autophagy-lysosome pathway: Controls protein clearance

Mitochondrial dynamics: Affects energy metabolism

Synaptic function: Modulates neurotransmitter release

Neuroinflammation: Regulates microglial activation[@tolosa2022]

LRRK2 Kinase Inhibitors in Development

Multiple LRRK2 inhibitors have advanced through clinical development:

| Drug | Company | Mechanism | Stage |
|------|---------|-----------|-------|
| DNL151/DNL312 | Denali/Biogen | ATP-competitive | Phase 2/3 |
| BIIB122 | Biogen | ATP-competitive | Phase 2b |
| PF-06649751 | Pfizer | ATP-competitive | Phase 1 |

Key challenges addressed at MDS 2026:

Blood-brain barrier penetration optimization
Peripheral toxicity mitigation (kidney, lung)
Patient selection through genetic testing
Biomarker development for target engagement

LRRK2 Gene Therapy Approaches

Novel therapeutic modalities include:

Antisense oligonucleotides (ASOs): Reduce LRRK2 expression
RNAi approaches: Viral-delivered shRNA targeting mutant alleles
CRISPR-based editing: Mutation-specific correction strategies

See [LRRK2 Pathway in PD](/mechanisms/pd-lrrk2-pathway) for detailed mechanism coverage.

2. GBA-Associated Parkinson's Disease

Genetic Background

[Glucocerebrosidase (GBA1)](/genes/gba) variants are the most significant genetic risk factor for sporadic PD, with 5-10% of PD patients carrying pathogenic variants[@gba2024].

Clinical Characteristics

GBA-PD represents a distinct clinical subtype:

Earlier age at onset: Mean 5-10 years earlier
Faster cognitive decline: Higher risk of PD dementia
Earlier autonomic dysfunction: Orthostatic hypotension, GI symptoms
Distinct sleep architecture: RBD may precede motor symptoms
Higher non-motor symptom burden: Anxiety, depression, anosmia

Molecular Mechanisms

| Pathway | Dysfunction | Therapeutic Target |
|---------|-------------|-------------------|
| Lysosomal function | ↓ GCase activity | Enzyme enhancement |
| Alpha-synuclein clearance | ↑ Aggregation | Ambroxol, substrate reduction |
| Lipid metabolism | ↑ Glucosylceramide | Substrate reduction therapy |
| Autophagy | Impaired clearance | Autophagy inducers |

Therapeutic Approaches

Ambroxol: Chaperone activity restores GCase function

Gene therapy (AAV-GBA): Restores enzyme expression

Substrate reduction therapy: Reduces glucosylceramide accumulation

Small molecule chaperones: Oral small molecule enhancers

See [GBA Pathway in PD](/mechanisms/gba-pathway-parkinsons) for detailed coverage.

3. Alpha-Synuclein Biology

SNCA Gene Variants

[SNCA](/genes/snca) encodes alpha-synuclein, the key protein in Lewy body pathology:

| Variant | Effect | Phenotype |
|---------|--------|-----------|
| A53T (SNCAm) | Early onset | Rapid progression, autonomic dysfunction |
| A30P | Incomplete penetrance | Variable |
| Triplication | Gene dose effect | Early onset, severe dementia |
| Duplication | Gene dose effect | Typical PD presentation |

Seed Amplification Assays (SAAs)

MDS 2026 featured updates on clinical validation of alpha-synuclein SAAs:

| Assay | Sensitivity | Specificity | Sample |
|-------|-------------|-------------|--------|
| RT-QuIC (CSF) | 87-95% | 90-95% | CSF |
| PMCA (CSF) | 88-96% | 92-98% | CSF |
| SynuLight (blood) | 80-85% | 85-90% | Blood |

Key applications:

Differential diagnosis of synucleinopathies
Pre-motor detection in at-risk populations
Disease progression monitoring
Clinical trial enrichment

Molecular Mechanisms of Aggregation

Post-translational modifications: Phosphorylation (Ser129), ubiquitination

Oligomer formation: Toxic soluble oligomers

Prion-like spreading: Cell-to-cell transmission

Membrane binding: Pore formation, calcium dysregulation

Impaired clearance: Autophagy-lysosome, ubiquitin-proteasome

See [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway) for detailed mechanisms.

4. PARK Genes and Monogenic PD

Autosomal Recessive Forms

| Gene | PARK Number | Protein Function | Phenotype |
|------|-------------|-----------------|-----------|
| [PRKN](/genes/parkin) (PARK2) | PARK2 | E3 ubiquitin ligase | Early onset, dystonia |
| [PINK1](/genes/pink1) (PARK6) | PARK6 | Mitochondrial kinase | Early onset |
| [DJ-1](/genes/park7) (PARK7) | PARK7 | Oxidative stress response | Early onset |
| [ATP13A2](/genes/atp13a2) (PARK9) | PARK9 | Lysosomal ATPase | Juvenile parkinsonism, dementia |

Autosomal Dominant Forms

| Gene | PARK Number | Protein Function | Phenotype |
|------|-------------|-----------------|-----------|
| [SNCA](/genes/snca) (PARK1/4) | PARK1/4 | Synaptic protein | Early onset, dementia |
| [LRRK2](/genes/lrrk2) (PARK8) | PARK8 | Kinase/GTPase | Typical PD |
| [VPS35](/genes/vps35) (PARK17) | PARK17 | Retromer component | Late onset, good levodopa response |

Emerging Genes

Recent discoveries include:

DNAJC13: Endosomal trafficking
CHCHD2: Mitochondrial function
RIC3: Acetylcholine receptor assembly
VPS13C: Mitochondrial quality control

5. Emerging Genetic Risk Factors

Multi-Ethnic GWAS Findings

Large-scale GWAS have identified >90 PD risk loci. Key findings from recent multi-ethnic studies:

| Population | Novel Loci | Notable Genes |
|------------|------------|---------------|
| European | 78 loci | LRRK2, GBA, SNCA |
| East Asian | 15 loci | FAM47E, SCARB2 |
| African | Novel variants | Population-specific |
| Latino | 8 loci | GCH1, MIR4697 |

Polygenic Risk Scores

Clinical implementation of PRS is advancing:

Risk stratification: Identifying high-risk individuals
Age at onset prediction: Modest predictive value
Progression modeling: Correlates with clinical outcomes
Therapeutic response: May predict levodopa response

Gene-Environment Interactions

MDS 2026 highlighted gene-environment interplay:

LRRK2 + pesticide exposure: Synergistic risk
GBA + smoking: Modifies risk
PRKN + traumatic brain injury: Increased vulnerability

6. Molecular Mechanisms Integration

Pathway Cross-Talk

Mermaid diagram (expand to render)

Convergence on Common Pathways

Protein homeostasis: Autophagy, UPS, chaperone systems

Mitochondrial quality control: Mitophagy, dynamics

Lysosomal function: Catabolism, trafficking

Synaptic transmission: Vesicle cycling, neurotransmission

Neuroinflammation: Microglial activation, cytokine release

7. Therapeutic Implications

Precision Medicine Approaches

| Genetic Subtype | Therapeutic Strategy | Development Stage |
|-----------------|-------------------|------------------|
| LRRK2 G2019S | Kinase inhibitors | Phase 2/3 |
| GBA1 | Enzyme enhancement | Phase 2 |
| SNCA | Immunotherapy | Phase 2/3 |
| PRKN/PINK1 | Mitophagy activators | Preclinical |
| ATP13A2 | Lysosomal function | Preclinical |

Biomarker Development

Genetic testing: Clinical implementation
Fluid biomarkers: α-syn SAAs, NFL, p-tau
Imaging biomarkers: Tau PET, dopamine imaging
Digital biomarkers: Wearable movement analysis

8. Clinical Implementation

Genetic Testing Recommendations

Tier 1 (all PD patients):

GBA sequencing
LRRK2 G2019S (population-specific)
SNCA analysis

Tier 2 (early onset, family history):

PRKN, PINK1, DJ-1
[VPS35](/genes/vps35)
[ATP13A2](/genes/atp13a2)

Genetic Counseling

Key considerations:

Pre-test counseling
Variant interpretation
Cascade testing options
Reproductive implications

[LRRK2 Gene](/genes/lrrk2)
[GBA Gene](/genes/gba)
[SNCA Gene](/genes/snca)
[Alpha-Synuclein Protein](/proteins/alpha-synuclein)
[LRRK2 Pathway in PD](/mechanisms/pd-lrrk2-pathway)
[GBA Pathway in PD](/mechanisms/gba-pathway-parkinsons)
[Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
[Parkinson's Disease](/diseases/parkinsons-disease)
[MDS 2026 — Genetics and Biomarkers](/biomarkers/mds-2026-genetics-biomarkers-movement-disorders)
[Multi-Ethnic PD GWAS](/mechanisms/multi-ethnic-pd-gwas)

10. References

[MDS Congress 2026](https://www.mdscongress.org)

[Cookson MR, The role of LRRK2 in Parkinson's disease. Nat Rev Neurosci 2023](https://doi.org/10.1038/s41583-023-00700-5)

[Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease. Transl Neurodegener 2024](https://pubmed.ncbi.nlm.nih.gov/39267121/)

[Alessi DR, Sammler E. LRRK2 kinase in Parkinson's disease. Science 2018](https://doi.org/10.1126/science.aar5009)

[Tolosa E, Vila M. LRRK2 in Parkinson disease: Challenges of clinical trials. Nat Rev Neurol 2022](https://doi.org/10.1038/s41582-022-00708-8)

This page synthesizes content relevant to MDS 2026 presentations on PD genetics and molecular mechanisms. For the latest updates, check the [MDS Congress website](https://www.mdscongress.org).

References

alessi2018, LRRK2 kinase in Parkinson's disease (2018)
cookson2023, The role of LRRK2 in Parkinson's disease (2023)
gba2024 (2024)
mds2026, MDS Congress 2026 (2026) [1](https://www.mdscongress.org)
tolosa2022, LRRK2 in Parkinson disease: Challenges of clinical trials (2022)

📖 View canonical wiki page →

MDS 2026 — PD Genetic and Molecular Mechanisms

MDS 2026 — Parkinson's Disease Genetic and Molecular Mechanisms

Overview

1. LRRK2 Pathway and Therapeutic Targeting

Genetic Basis

Molecular Mechanisms

MDS 2026 — Parkinson's Disease Genetic and Molecular Mechanisms

Overview

1. LRRK2 Pathway and Therapeutic Targeting

Genetic Basis

Molecular Mechanisms

LRRK2 Kinase Inhibitors in Development

LRRK2 Gene Therapy Approaches

2. GBA-Associated Parkinson's Disease

Genetic Background

Clinical Characteristics

Molecular Mechanisms

Therapeutic Approaches

3. Alpha-Synuclein Biology

SNCA Gene Variants

Seed Amplification Assays (SAAs)

Molecular Mechanisms of Aggregation

4. PARK Genes and Monogenic PD

Autosomal Recessive Forms

Autosomal Dominant Forms

Emerging Genes

5. Emerging Genetic Risk Factors

Multi-Ethnic GWAS Findings

Polygenic Risk Scores

Gene-Environment Interactions

6. Molecular Mechanisms Integration

Pathway Cross-Talk

Convergence on Common Pathways

7. Therapeutic Implications

Precision Medicine Approaches

Biomarker Development

8. Clinical Implementation

Genetic Testing Recommendations

Genetic Counseling

9. Related Pages

10. References

References